Results 171 to 180 of about 422,254 (259)

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides

ESC Heart Failure, Volume 12, Issue 2, Page 879-887, April 2025.
Abstract Background Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF). Aims This study aimed to characterize patients with exertional dyspnoea and normal/near‐to‐normal N‐terminal pro‐brain natriuretic peptide (NT ...
Emmanuelle Berthelot, Tarek Laouar, Antoine Beurnier, Nataliya Hrynchynshyn, Jean Christophe Eicher, Jean‐Michel Tartière, Patrick Jourdain, Olivier Lairez, Barnabas Gellen   +8 more
wiley   +1 more source

Risk of bleeding in transbronchial biopsies in patients with pulmonary hypertension. [PDF]

Sci Rep
Lutz JR, Galindo JL, Barbosa V.
europepmc   +1 more source

Heart-Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction. [PDF]

Compr Physiol
Prabala P, Raza F, Chesler NC.
europepmc   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Sotatercept for the Treatment of Myeloproliferative Neoplasm-Associated Group 5 Pulmonary Hypertension. [PDF]

JACC CardioOncol
Ali HR, Faiz SA, Deswal A, Palaskas N, Iliescu C, Thompson K, Ohanian M, Pemmaraju N, Bose P, Sahay S.   +9 more
europepmc   +1 more source

Multi-Omics Identification of Biomarkers for High-Altitude Pulmonary Hypertension. [PDF]

J Cardiovasc Dev Dis
Chen Z, Pang L, Zheng Y, Xu L, Tang M, Zhao Z, Wang T, Li J, Zhou Y, Duo L, Zhu W, Luo Z, Li F, Zhu D.   +13 more
europepmc   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Dynamin 2 Regulates Mitochondrial Mitotic Fission in Pulmonary Hypertension. [PDF]

Circ Res
Dasgupta A, Chen KH, Wu D, Yerramilli VS, Lima PDA, Martin AY, Bentley RET, Ott BP, Nandani T, Mewburn JD, Tian L, Al-Qazazi R, Emon IM, Colpman P, Jefferson L, Noordhof C, Jones O, Hindmarch CCT, Archer SL.   +18 more
europepmc   +1 more source